
Atopic Dermatitis
Latest News
Latest Videos

CME Content
More News


Lifestyle recommendations are an interesting and complex aspect of eczema care. There are many things that can impact eczema severity and are in a patient's control to a certain extent. However, offering suggestions that can actually help patients can be challenging, one expert says.

Adult atopic dermatitis patients with moderate-to-severe disease who were treated with systemic agents reported a high level of disease-related burden despite those treatments, says a recent study.

Bathing in a 0.5% apple cider vinegar solution isn’t a useful treatment for atopic dermatitis, and it can be irritating to the skin, report researchers in a recent study.

Stay up-to-date on the most recent clinical advances in atopic dermatitis.

In this interview, Dr. Anna De Benedetto discusses what initially drew her to dermatology and what inspired her to study atopic dermatitis in the elderly.

Adults 60 years and older tend to have a distinct atopic dermatitis presentation and important comorbidities, but dermatologists treating these patients find lacking evidence on how to diagnose and best treat atopic dermatitis in the elderly, according to a recent review.

A recent review provides a timely update regarding what is known about itch and skin barrier damage.

A recent study in experimental mice showed that interleukin-4 and interleukin-13 act as acute pruritogens, supporting the benefit of targeting these cytokines in the therapeutic planning of the patients with pruritus.

A study recently investigated the effects of probiotics on clinical symptoms, immune response, and gut microbiota in patients with atopic dermatitis. Dr. Lazzara explains what researchers discovered in this video.


Real-world outcomes from treating adults with moderate-to-severe atopic dermatitis with dupilumab are similar to what researchers have found in clinical trials, according to this study.

Pain is a distinct and important symptom of atopic dermatitis experienced by almost two thirds of patients, reports a recent study.

Researchers recently analyzed insurance claims data to investigate the safety and efficacy of off-label immunomodulatory drugs for atopic dermatitis in real life practice. Read what they discovered here.

Atopic dermatitis presents differently depending on whether the patient is an adult or child. This means that different treatments may be more effective in an adult than children and vice versa.

Dermatologists investigate better ways to treat radiodermatitis as it becomes increasingly common in breast cancer patients.

Niki Vora reflects on how her struggles with untreated atopic dermatitis, folliculitis and cystic acne led her to writing her scholarship-winning essay.

Psoriasis and atopic dermatitis patients want more nonsteroidal topical options. This expert breaks down newly available treatments and those to come.

A third of the most viewed eczema videos on YouTube give misleading and potentially harmful information, says a recent study.

In this Medical News Minute, Dr. Lazzara discusses the findings of a recent study that examined the dosage of an experimental drug for the treatment of itchy skin in people with atopic dermatitis.

Dermatologists should not depend on a rescue approach for atopic dermatitis flares, says a recent paper. Instead, they should talk with patients about newer treatment options that could offer long-term disease with minimal adverse events.

The realization of the critical importance of the IL-17 and 23 pathways have led to the development of numerous therapies that target parts of the immune system.

Insights offer greater understanding around patient perspectives and desires that could prove useful to dermatologists in managing atopic dermatitis and psoriasis.

LEO Pharma has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for the study of an oral atopic dermatitis treatment, JW1601/LP0190, according to a company announcement.

Research suggests that early-, mid-, and late-onset pediatric AD may be clinically distinct disease subtypes and that age of onset could be used to risk stratify patients.







